(DTRA who MADE Sars-Cov-2 (Covid-19) and unleashed it during World Games 2019 in Wuhan, China THEN got Remdesivir approved by FDA thru Emergency Use Authorization as a treatment for people sick with Covid in early summer of 2020 thus ensuring MORE DEATHS to be attributed to Covid. You can't make this shit up folks)
from Dvids
The COVID pandemic took the world by surprise. Researchers were left
scrambling to devise a way to best mitigate the negative impact this
disease has on global health. However, at the Defense Threat Reduction
Agency (DTRA) it is common to operate in the “what if” space when it
comes to potential biological threats. In fact, DTRA investments in
technologies that detect, mitigate, or neutralize chemical and
biological threats to the military and the nation date back more than 20
years.
“In late 2019, DTRA started a new program called Discovery of Medical
Countermeasures Against Novel Entities (DOMANE) to address novel and
emerging threats,” stated Dr. David Hone, Chief Scientist within the
Vaccines and Therapeutics Division at DTRA. “Based on previous work, we
decided DOMANE would not only focus on FDA-approved drugs but also
combination therapeutics, as we believe that no single drug will be
completely effective in treating new diseases. COVID-19 has provided us
an opportunity to test our hypotheses using DOMANE.”
DOMANE provides rapid decision-making capabilities to identify
FDA-approved drugs that will most likely be effective therapeutics for
COVID-19. Repurposing candidate drugs from a pool about 7,500
FDA-approved drugs to advance an effective COVID-19 therapeutic allows
for a more rapid response in developing a therapeutic regimen. The
end-result is a response that modifies COVID-19 in treated patients and
promotes a speedy recovery.
Veklury®, which is more commonly referred to as Remdesivir, is a
ribonuclease inhibitor developed by Gilead Sciences. It delivers
broad-spectrum antiviral activity and has proven to be a modestly
effective therapeutic for the treatment of COVID-19. Originally
developed as an Ebola Zaire countermeasure, this DTRA-funded inhibitor
transitioned for more advanced testing due to promising pre-clinical
trials. Remdesivir inhibits viral replication in a wide variety of
pathogens and was one of the first therapeutics identified in the
Defense Department for repurposing to treat COVID-19. In the summer of
2020, Remdesivir received authorization for emergency use only in
COVID-19 patients with continued FDA oversight...
read more here
No comments:
Post a Comment